CCR1 and rheumatoid arthritis: In previous studies, prednisolone and a CCR1 antagonist resulted in 40% to 50% reduction in sublining macrophages over 12 to 14 weeks in controlled studies, while in contrast patients receiving placebo or stable background therapy demonstrated a 10% to 25% increase in sublining macrophages.[34,36] The RAMRIS criteria for MRI improvement reflect those observed in a 12 week phase II study of fostamatinib (Syk kinase inhibitor) in RA, albeit a much larger study than the current one.[40] The RAMRIS score in the placebo group of that study increased (indicating disease progression).